Skip to main content

Iran health authorities say public will get vaccine jabs in September

The new promise marks yet another delay of previously announced plans for an inclusive national vaccination rollout highly demanded by the Iranian public.
An Iranian health worker prepares an injection of the locally-made COVID-19 vaccine during the start of the second phase of trials in the capital Tehran on March 15, 2021.

Iran's health officials said June 1 that a far-reaching coronavirus vaccination program will start in September. The statement was last in a series of unfulfilled promises with varying dates for a much-needed vaccination plan covering all members of the public.

According to the spokesman for Iran's National Coronavirus Task Force, Alireza Raisi, the public phase will kick off once several designated high-risk groups have received their two jabs. The program, he said, will continue until the end of 2021. 

Iran's rollout began with frontline medical staff in all hospitals nationwide in February. Months on, the piecemeal program has reached senior citizens at the age of 70, with only 3.7 million Iranians of the entire population of 85 million having received their first jab.

The vaccination has been administered with multiple imported products, the bulk of which has been supplied by Russian Sputnik V and the Chinese Sinopharm. But Iran has been hoping to accelerate the process using its own domestically developed vaccine, known as the COV Iran Barakat. The project has been spearheaded by the Executive Headquarters of the Imam Directive, a financial empire that only reports to Iran's Supreme Leader Ayatollah Ali Khamenei. The center said it will have produced some 30 million doses by September.

Earlier this week, the producer also said as many as 1 million doses are now ready to be administered before being delivered to the Health Ministry. The vaccine's first trial was conducted December last year and the mass production line was launched in late May. Iran's health officials have offered assurances about the efficacy of the vaccine, also boasting about "a backlog" of requests from Iranians for voluntary shots. 

Much of the vaccination of those under the age of 60 is now planned to be carried out using the same Iranian product. As the vaccine has yet to pass international approvals, the announcement has fuelled concerns among some Iranians, who have previously cast their distrust on the homemade vaccine.

During the pandemic's peaks over the past 14 months, Iran has seen only a few brief periods of respite while it has continued to be the Middle East's worst-hit nation. Some 3 million cases have been officially confirmed since the onset of the pandemic that has claimed over 80,000 lives.

After an exponential growth in May, the Health Ministry is now expecting the daily mortalities to fall back to two-digit figures by the end of June. Amid the slow-paced rollout, which has been characterized with corruption and a lack of transparency, such positive statements could mean a lowered guard and have sparked fears about a looming "fifth wave" of deaths and infections.

Join hundreds of Middle East professionals with Al-Monitor PRO.

Business and policy professionals use PRO to monitor the regional economy and improve their reports, memos and presentations. Try it for free and cancel anytime.

Free

The Middle East's Best Newsletters

Join over 50,000 readers who access our journalists dedicated newsletters, covering the top political, security, business and tech issues across the region each week.
Delivered straight to your inbox.

Free

What's included:
Our Expertise

Free newsletters available:

  • The Takeaway & Week in Review
  • Middle East Minute (AM)
  • Daily Briefing (PM)
  • Business & Tech Briefing
  • Security Briefing
  • Gulf Briefing
  • Israel Briefing
  • Palestine Briefing
  • Turkey Briefing
  • Iraq Briefing
Expert

Premium Membership

Join the Middle East's most notable experts for premium memos, trend reports, live video Q&A, and intimate in-person events, each detailing exclusive insights on business and geopolitical trends shaping the region.

$25.00 / month
billed annually

Become Member Start with 1-week free trial

We also offer team plans. Please send an email to pro.support@al-monitor.com and we'll onboard your team.

What's included:
Our Expertise AI-driven

Memos - premium analytical writing: actionable insights on markets and geopolitics.

Live Video Q&A - Hear from our top journalists and regional experts.

Special Events - Intimate in-person events with business & political VIPs.

Trend Reports - Deep dive analysis on market updates.

All premium Industry Newsletters - Monitor the Middle East's most important industries. Prioritize your target industries for weekly review:

  • Capital Markets & Private Equity
  • Venture Capital & Startups
  • Green Energy
  • Supply Chain
  • Sustainable Development
  • Leading Edge Technology
  • Oil & Gas
  • Real Estate & Construction
  • Banking

Start your PRO membership today.

Join the Middle East's top business and policy professionals to access exclusive PRO insights today.

Join Al-Monitor PRO Start with 1-week free trial